The pediatric gastroenterology clinic nurse’s communication challenge
The pediatric gastroenterology clinic nurse works in a specialty where the gap between what a family can observe and what is happening in the child’s body is wider than almost anywhere in pediatric medicine. Three communication patterns recur with unusual frequency in the pediatric GI clinic.
The first is the treatment-intensity paradox: parents who have been told that their child has an inflammatory bowel disease are then told that the recommended first treatment is a biologic medication — a category they associate with chemotherapy, severe autoimmune disease, and cancer treatment. They have researched mesalamine. They know it exists. They have read that it is used for IBD. They cannot understand why the gastroenterologist is not starting there. The answer requires explaining not just that mesalamine is insufficient for Crohn’s disease but why — the transmural versus mucosal distinction — and then explaining a second, pediatric-specific reason that does not arise in adult IBD care at all: that the inflammatory cytokines from active transmural intestinal disease are quietly suppressing their child’s growth plate function at exactly the developmental window that cannot be recovered.
The second is the healthy-infant surgical urgency paradox: a 7-week-old infant who is nursing, gaining weight, making eye contact, and appearing completely normal to his grandmother’s experienced eye is described by the surgical team as having a condition requiring major abdominal surgery within 48 hours. The grandmother has raised children and grandchildren. She knows what a sick infant looks like. This baby does not look sick. The challenge is explaining that the process determining whether surgery can help is running on an independent timeline that has nothing to do with what the baby looks like today, and that the baby looking healthy is not a reason to delay — it is the narrow window in which the surgery can work.
The third is the TPN-when-feeding-works paradox: parents who have watched their premature daughter survive emergency surgery, recover from necrotizing enterocolitis, and begin tolerating small amounts of breast milk are told she will need intravenous nutrition through a central line for another 6 to 9 months. They can see that she is eating. They can see that she is tolerating it. They cannot understand why the eating is not enough. The explanation requires introducing a concept that is genuinely counterintuitive: that the enteral feeds and the TPN are doing different jobs simultaneously, and that doing both together is the only path toward eventually doing neither.
Three conversations from the pediatric gastroenterology clinic:
Scenario 1: Lucas Ramírez-Ochoa — 12, seventh-grader from Houston, Texas
Lucas Ramírez-Ochoa had been a healthy child until the previous spring. His parents had first noticed that he seemed to be eating less, that he was complaining about stomach pain after lunch at school, and that he had lost weight — from 42 kg in January to 37 kg in May, which his pediatrician had noted was a drop from the 35th percentile to the 10th for his age. He had had no bloody diarrhea, no fever, no vomiting. His mother Daniela had assumed it was the stress of starting middle school. His father Carlos had thought it might be lactose intolerance.
The pediatrician had ordered a fecal calprotectin. The result had come back at 1,620 micrograms per gram. The pediatrician had called Daniela the same day and referred them urgently to pediatric gastroenterology. A week later, a complete IBD workup had been done: CRP 3.8 mg/dL, ESR 47, hemoglobin 10.4 g/dL, albumin 3.2 g/dL. An MRI enterography had shown a 22-centimeter segment of terminal ileum with transmural wall thickening, mucosal hyperenhancement, and mesenteric fat stranding, plus skip lesions in the ascending colon with deep aphthous ulcers and a cobblestone mucosal pattern. The gastroenterologist had performed an ileocolonoscopy with biopsies that showed non-caseating granulomas in three locations. The diagnosis was Crohn’s disease, ileocolonic, moderate to severe activity.
The gastroenterologist had recommended infliximab — intravenous infusions at weeks 0, 2, and 6, then every 8 weeks. She had also recommended starting azathioprine as combination therapy to reduce immunogenicity.
Daniela had gone home and researched everything. She had found mesalamine. She had read that it was used for IBD. She had also read about biologic medications and their side effects: infection risk, lymphoma risk (rare but mentioned in every article she found), demyelinating disease. She had printed the prescribing information for infliximab and highlighted everything that appeared under “warnings.”
She and Carlos were in the nursing education visit before the first infusion with the highlighted printout and one question written at the top of it in capital letters: ¿POR QUÉ EL MEDICAMENTO MÁS FUERTE PRIMERO?
Pediatric gastroenterology clinic nurse Rosa Contreras-Villanueva had been doing infliximab start consultations for eleven years. She had learned that Daniela’s question was not a challenge to the plan — it was a parent trying to understand what had happened to her son’s health and why the treatment being offered was what it was. She took the printout gently, set it to one side, and started with the part of the answer Daniela had not been able to find online.
“Señora Daniela, la pregunta que usted escribió — ¿por qué el medicamento más fuerte primero? — asume algo que es válido para muchas enfermedades pero no para esta. Asume que la mesalamina es una versión más débil del mismo tratamiento. Y entiendo por qué llegó a esa conclusión — los dos se usan en enfermedad inflamatoria intestinal. Pero hacen cosas fundamentalmente diferentes en dos enfermedades que son diferentes entre sí. Necesito explicarle la diferencia, porque eso responde la pregunta.” (Mrs. Daniela, the question you wrote — why the strongest medication first? — assumes something that is valid for many diseases but not this one. It assumes that mesalamine is a weaker version of the same treatment. And I understand why you reached that conclusion — both are used in inflammatory bowel disease. But they do fundamentally different things in two diseases that are different from each other. I need to explain the difference, because that answers the question.)
Carlos leaned forward. “¿Son enfermedades diferentes?” (They are different diseases?)
“Son lo que llamamos el mismo espectro, pero con una diferencia que cambia todo: la colitis ulcerosa, donde la mesalamina funciona bien, tiene inflamación solo en la capa más interna del intestino — la mucosa, la capa de tejido que está en contacto con el interior. La mesalamina llega ahí. La enfermedad de Crohn tiene inflamación en todas las capas de la pared — la mucosa, las capas del medio, el músculo, y la capa externa. La mucosa es solo la primera de cuatro capas. La mesalamina no llega a las capas que están adentro.” (They are what we call the same spectrum, but with a difference that changes everything: ulcerative colitis, where mesalamine works well, has inflammation only in the innermost layer of the intestine — the mucosa, the tissue layer in contact with the interior. Mesalamine reaches there. Crohn’s disease has inflammation in all the layers of the wall — the mucosa, the middle layers, the muscle, and the outer layer. The mucosa is only the first of four layers. Mesalamine does not reach the layers that are deeper inside.)
Daniela stared at the printout she had highlighted. “¿Entonces la mesalamina no funciona para el Crohn?” (So mesalamine does not work for Crohn’s?)
“Los estudios que han comparado la mesalamina con placebo en la enfermedad de Crohn — estudios randomizados, con muchos pacientes — no encuentran diferencia estadística. No es que la mesalamina sea un poco menos efectiva. Es que no hay evidencia de que funcione en Crohn en absoluto, porque el blanco de la mesalamina es una capa a la que la enfermedad de Lucas no está limitada. Por eso no la recomendamos ni como primer paso: no es un paso conservador, es un paso que no llevaría a ninguna parte.” (The studies that have compared mesalamine to placebo in Crohn’s disease — randomized studies, with many patients — find no statistical difference. It is not that mesalamine is slightly less effective. It is that there is no evidence that it works in Crohn’s at all, because the target of mesalamine is a layer to which Lucas’s disease is not confined. That is why we do not recommend it even as a first step: it is not a conservative step, it is a step that would not go anywhere.)
Carlos was quiet for a moment. He was working through the math. “¿Y los esteroides? Los esteroides también se usan para la inflamación.” (And steroids? Steroids are also used for inflammation.)
“Buena pregunta. Los esteroides controlan los síntomas — el dolor de Lucas, la pérdida de peso, la anemia que tiene ahora. Si le diéramos esteroides hoy, en dos semanas Lucas probablemente se sentiría mucho mejor. Eso no es lo mismo que curar el intestino. Los esteroides reducen la inflamación clínicamente, pero en la mayoría de los niños con Crohn moderado a severo no producen lo que llamamos curación de la mucosa — que el intestino no tenga úlceras cuando lo vemos con la cámara. Y eso importa porque la pregunta no es solo cómo se siente Lucas ahora.” (Good question. Steroids control symptoms — Lucas’s pain, the weight loss, the anemia he has now. If we gave him steroids today, in two weeks Lucas would probably feel much better. That is not the same as healing the intestine. Steroids reduce inflammation clinically, but in most children with moderate-to-severe Crohn’s they do not produce what we call mucosal healing — the intestine having no ulcers when we look with the camera. And that matters because the question is not only how Lucas feels now.)
Daniela looked up. “¿Cuál es la pregunta?” (What is the question?)
“La pregunta es cómo va a estar el intestino de Lucas en cinco y diez años. Las úlceras profundas en la pared del intestino — las que muestran las imágenes de Lucas — producen cicatrices con el tiempo. Las cicatrices acumuladas en la pared del intestino producen estenosis — estrechamientos que pueden bloquear el intestino y requerir cirugía. Las úlceras que penetran a través de la pared del intestino producen fístulas — túneles anormales que se pueden abrir a otros órganos. Esas complicaciones no ocurren en semanas — ocurren en años. Y el predictor más fuerte de si ocurrirán es si el intestino de Lucas sana por dentro ahora, no si los síntomas mejoran ahora.” (The question is how Lucas’s intestine will be in five and ten years. The deep ulcers in the intestinal wall — the ones that show in Lucas’s imaging — produce scar tissue over time. The accumulated scar tissue in the intestinal wall produces strictures — narrowings that can block the intestine and require surgery. Ulcers that penetrate through the intestinal wall produce fistulas — abnormal tunnels that can open to other organs. Those complications do not happen in weeks — they happen in years. And the strongest predictor of whether they will happen is whether Lucas’s intestine heals on the inside now, not whether the symptoms improve now.)
Carlos was nodding slowly. He was a licensed electrician; he thought in systems. “Entonces el objetivo del tratamiento no es que Lucas no tenga dolor.” (So the treatment goal is not for Lucas to have no pain.)
“No solo eso. El objetivo es que cuando volvamos a hacer la colonoscopía en seis meses, el intestino de Lucas no tenga úlceras. Que el calprotectin fecal baje a menos de 150. Que la pared del intestino en la resonancia se vea normal. Eso se llama curación de la mucosa. El infliximab alcanza ese objetivo en aproximadamente el 55 o 60 por ciento de los niños con Crohn moderado a severo. Los enfoques que empiezan por esteroides y van escalando llegan ahí en el 25 al 35 por ciento, y tarden más — lo que significa más tiempo con úlceras activas.” (Not only that. The goal is that when we do the colonoscopy again in six months, Lucas’s intestine has no ulcers. That the fecal calprotectin drops below 150. That the intestinal wall on MRI looks normal. That is called mucosal healing. Infliximab achieves that goal in approximately 55 to 60 percent of children with moderate-to-severe Crohn’s. Approaches that start with steroids and escalate reach it in 25 to 35 percent, and take longer — which means more time with active ulcers.)
Rosa paused. There was one more piece of this conversation that was specific to Lucas being twelve years old, and she had learned to be direct about it.
“Hay algo más que quiero que entiendan, porque no se aplica a los adultos con Crohn y a veces las familias no lo saben hasta que ya pasó el momento. Lucas pesa 37 kilos y está en el percentil 10 de estatura para su edad. La inflamación activa del Crohn moderado a severo produce citocinas — mensajeros inflamatorios — que inhiben directamente la señal de crecimiento en los cartílagos de los huesos. El sistema que le dice a los huesos de Lucas que crecer necesita IGF-1, y la inflamación activa reduce la producción de esa señal en el hígado. En los niños con Crohn activo moderado a severo, eso puede traducirse en una pérdida de aproximadamente 1 a 2 centímetros de estatura adulta por año de enfermedad activa. Y cuando los cartílagos de crecimiento cierren en la pubertad, esa estatura no se recupera. El peso sí se puede recuperar. La estatura no.” (There is something else I want you to understand, because it does not apply to adults with Crohn’s and sometimes families do not learn it until the moment has already passed. Lucas weighs 37 kilos and is at the 10th percentile for height for his age. The active inflammation of moderate-to-severe Crohn’s produces cytokines — inflammatory messengers — that directly inhibit the growth signal in the cartilages of the bones. The system that tells Lucas’s bones to grow needs IGF-1, and active inflammation reduces the production of that signal in the liver. In children with active moderate-to-severe Crohn’s, that can translate into a loss of approximately 1 to 2 centimeters of adult height per year of active disease. And when the growth cartilages close in puberty, that height is not recovered. Weight can be recovered. Height cannot.)
The room was quiet. Daniela had set her pen down. Carlos was looking at Lucas, who was sitting in the corner of the consultation room scrolling through his phone, unaware of the significance of the last three minutes.
“¿El infliximab detiene eso?” Daniela asked. (Infliximab stops that?)
“Si logra la curación de la mucosa, sí. La normalización de la inflamación restaura la señal de IGF-1 y el crecimiento vuelve. Los estudios muestran que los niños con Crohn que alcanzan curación mucosa en los primeros seis meses de tratamiento recuperan la velocidad de crecimiento normal. El objetivo del infliximab no es solo que el intestino de Lucas no tenga síntomas — es que el intestino de Lucas sane antes de que la ventana de crecimiento de Lucas se cierre.” (If it achieves mucosal healing, yes. The normalization of inflammation restores the IGF-1 signal and growth returns. Studies show that children with Crohn’s who achieve mucosal healing in the first six months of treatment recover normal growth velocity. The goal of infliximab is not only that Lucas’s intestine has no symptoms — it is that Lucas’s intestine heals before Lucas’s growth window closes.)
Carlos looked at his son. “Lucas — ven a sentarte aquí.” (Lucas — come sit here.) He wanted his son to hear what had just been said.
Daniela turned back to Rosa with one final question. “¿Y los riesgos del infliximab que leí en el formulario?” (And the risks of infliximab I read in the form?)
“Son reales y los tomamos en serio. El riesgo más importante en los niños es infecciones — sobre todo infecciones respiratorias — y hay que vacunar contra neumonoco y gripe antes de empezar. El riesgo de linfoma que mencionó el formulario en pediatría es muy bajo y se estudia en series grandes — en la balanza, el riesgo de que el Crohn activo de Lucas produzca estenosis intestinales o complicaciones quirúrgicas en la adolescencia es significativamente mayor que el riesgo de linfoma por el infliximab. No lo decimos para minimizar el riesgo — lo decimos porque esa es la balanza real que la evidencia muestra.” (They are real and we take them seriously. The most important risk in children is infections — especially respiratory infections — and we need to vaccinate against pneumococcus and influenza before starting. The lymphoma risk mentioned in the form in pediatrics is very low and is studied in large series — on balance, the risk of Lucas’s active Crohn’s producing intestinal strictures or surgical complications in adolescence is significantly higher than the lymphoma risk from infliximab. We do not say this to minimize the risk — we say it because that is the real balance that the evidence shows.)
Daniela folded the highlighted printout and put it in her bag. The questions had been replaced with something that looked like readiness. “Explíquenos el día de la infusión.” (Explain the infusion day to us.)
Scenario 2: Tomás Vargas-Herrera — 49 days old, San Antonio, Texas
Tomás Vargas-Herrera was born at 38 weeks and four days — healthy, 3.4 kg, APGAR 9 at one minute. He had been circumcised on day 3 and sent home on day 4. His mother Gabriela, 25, a dental hygienist on maternity leave, had noticed that the yellow color that is normal in the first week — her obstetrician had said it was physiologic jaundice, common in breastfed infants — had not completely gone away. At two weeks, his skin was still faintly yellow. At three weeks, it was the same. At four weeks, she had taken him to his pediatrician’s office and pointed to his eyes: the whites were yellow.
The pediatrician had drawn a fractionated bilirubin. Direct bilirubin: 5.8 mg/dL. Total bilirubin: 8.2 mg/dL. Seventy percent of the bilirubin was the direct fraction — the fraction that meant the liver was not excreting bile normally, not the fraction from normal newborn red blood cell breakdown. The pediatrician had called the pediatric gastroenterology attending from the clinic room and arranged a same-day evaluation at Children’s Hospital San Antonio.
An abdominal ultrasound had shown an absent gallbladder and the triangular cord sign — a wedge-shaped echogenic density at the portal hepatis representing the obliterated extrahepatic bile ducts. A liver biopsy had shown the bile ductular proliferation and portal fibrosis consistent with biliary atresia. An intraoperative cholangiogram — injecting contrast directly into the biliary system while Tomás was under anesthesia — had confirmed complete obliteration of the extrahepatic bile ducts with no contrast flowing from the hepatic hilum into the intestine.
The pediatric surgeon had met with Gabriela and Miguel — Tomás’s father, 28, a construction foreman — and had recommended proceeding to Kasai portoenterostomy within 48 hours. Tomás was on day 49.
Esperanza, Gabriela’s mother, had driven up from Laredo when she heard there would be surgery. She had raised three children, she had had six grandchildren, and she had watched every one of them as infants with the attention of someone who had spent forty years reading infants’ faces. She had held Tomás since she arrived. He had looked up at her. He had nursed. He had fallen asleep on her shoulder.
She was in the family consultation room with Gabriela and Miguel when pediatric gastroenterology clinic nurse Carmen Espinoza-Reyes came to do the pre-surgical education. Miguel was holding Tomás. Esperanza had been quiet on the drive from the ultrasound results room, but the question she had been carrying since she arrived was now in the room with them.
“Enfermera — con todo el respeto al equipo médico — yo crié a tres hijos. He tenido seis nietos. Este niño come, sube de peso, me sigue con los ojos, está despierto y alerta. Tiene un poco de color, sí — pero eso puede ser la leche materna, o el hígado que está madurando. ¿Por qué hay que hacerle una cirugía mayor a un bebé de 49 días que se ve bien?” (Nurse — with all due respect to the medical team — I raised three children. I have had six grandchildren. This baby eats, gains weight, follows me with his eyes, is awake and alert. He has a little color, yes — but that could be the breast milk, or the liver maturing. Why does a 49-day-old baby who looks fine need major surgery?)
Gabriela had tears at the edge of her eyes. She had been trying to hold both things in mind simultaneously — the baby who looked and felt normal and the test results that said he was not — and she could not make them fit together.
Carmen had done this conversation perhaps two hundred times in her twelve years in pediatric GI. The grandmother was the most important person to reach, she had learned, not because she had formal authority but because she had the family’s deepest trust and the greatest capacity to either anchor or unsettle the decision in the hours before surgery.
“Señora Esperanza — la pregunta que usted hace es exactamente la que yo esperaba, y tiene razón en hacerla. Todo lo que usted observa de Tomás es verdad. Pero hay algo que no se puede ver desde afuera, y por eso quiero explicarle qué tipo de enfermedad es la atresia biliar — porque no es el tipo de enfermedad que muestra lo que está haciendo mientras lo está haciendo.” (Mrs. Esperanza — the question you are asking is exactly the one I expected, and you are right to ask it. Everything you observe about Tomás is true. But there is something that cannot be seen from the outside, and that is why I want to explain what kind of disease biliary atresia is — because it is not the kind of disease that shows what it is doing while it is doing it.)
She paused to make sure she had Esperanza’s attention.
“La atresia biliar no es que los conductos biliares nacieron estrechos y necesitan ensancharse. Es un proceso inflamatorio que está destruyendo los conductos biliares activamente, de adentro hacia afuera, desde que Tomás era un bebé muy pequeño en el útero. Los conductos biliares afuera del hígado — los que conectan el hígado con el intestino — ya están completamente destruidos. Eso lo confirmamos con el colangiograma de esta mañana. El mismo proceso está trabajíando ahora en los conductillos biliares microscópicos dentro del hígado, los que dan a la superficie del hígado donde se haría la conexión en la cirugía.” (Biliary atresia is not that the bile ducts were born narrow and need to be widened. It is an inflammatory process that is actively destroying the bile ducts, from inside out, since Tomás was a very small baby in the uterus. The bile ducts outside the liver — the ones connecting the liver to the intestine — are already completely destroyed. We confirmed that with the cholangiogram this morning. The same process is working right now on the microscopic bile ductules inside the liver, the ones that come to the surface of the liver where the surgical connection would be made.)
Esperanza was listening carefully. “¿Y la cirugía los repara?” (And surgery repairs them?)
“La cirugía de Kasai no repara los conductos — no se puede reconstruir lo que ya está destruido. Lo que hace es crear un camino alternativo. El cirujano corta el tejido obliterado en la puerta del hígado — donde los conductos solían salir — y conecta un segmento de intestino directamente a esa superficie del hígado, de manera que si todavía hay conductillos microscópicos funcionando en esa superficie, la bilis pueda salir directamente al intestino. La cirugía solo funciona si esos conductillos microscópicos todavía están ahí cuando llegamos a la superficie. Y ahí está el problema: ese mismo proceso inflamatorio los está destruyendo progresivamente. No hay ninguna imagen, ninguna prueba de sangre, que pueda mostrarnos en tiempo real cuántos quedan. Solo la cirugía puede saberlo.” (The Kasai surgery does not repair the ducts — what has already been destroyed cannot be reconstructed. What it does is create an alternative pathway. The surgeon cuts the obliterated tissue at the portal of the liver — where the ducts used to exit — and connects a segment of intestine directly to that surface of the liver, so that if there are still microscopic ductules functioning at that surface, bile can flow directly into the intestine. The surgery only works if those microscopic ductules are still there when we arrive at the surface. And there is the problem: that same inflammatory process is progressively destroying them. There is no image, no blood test, that can show us in real time how many remain. Only the surgery can know.)
Miguel had been very still. “¿Y si esperamos?” (And if we wait?)
“El proceso no espera. Cada día que pasa, ese proceso destruye más conductillos. Los datos de todos los niños que han tenido esta cirugía muestran lo siguiente: si la cirugía se hace antes de los 60 días, el 50 al 65 por ciento de los niños mantienen el hígado propio durante cinco años. Entre los días 60 y 90, ese porcentaje baja al 30 al 40 por ciento. Después de los 90 días, baja a menos del 15 por ciento — y después de los 120 días, la cirugía rara vez funciona.” (The process does not wait. Every day that passes, that process destroys more ductules. The data from all the children who have had this surgery shows the following: if surgery is done before day 60, 50 to 65 percent of children keep their own liver for five years. Between days 60 and 90, that percentage falls to 30 to 40 percent. After day 90, it falls below 15 percent — and after day 120, surgery rarely works.)
Esperanza closed her eyes briefly. “¿Cuántos días tiene Tomás?” (How many days does Tomás have?)
“Cuarenta y nueve.” (Forty-nine.)
The number landed quietly. Esperanza counted. Eleven days before the first threshold. She was a woman who had grown up in a family where waiting to see what happened was the default response to medical uncertainty. But the numbers were too clear.
“Usted dijo que el bebé se ve bien porque el hígado todavía está compensando.” (You said the baby looks well because the liver is still compensating.)
“Sí. La bilis que no puede drenar se acumula en los hepátocitos — las células del hígado — y produce daño celular con el tiempo. Pero el hígado tiene mucha reserva funcional; puede compensar el daño por meses antes de que aparezcan los signos de falla hepática. La cirrosis, la hipertensión portal, el sangrado de várices — eso ocurre si Tomás no recibe tratamiento efectivo, y ocurre en los primeros dos a tres años de vida. Pero cuando eso aparece, la ventana ya cerró. Tomás se ve bien porque estamos actuando ahora — antes de que empiece a verse mal. Eso es exactamente lo que necesitamos: actuar cuando todavía hay algo que la cirugía puede hacer.” (Yes. The bile that cannot drain accumulates in the hepatocytes — the liver cells — and produces cellular damage over time. But the liver has a lot of functional reserve; it can compensate for the damage for months before signs of liver failure appear. The cirrhosis, portal hypertension, variceal bleeding — that happens if Tomás does not receive effective treatment, and it happens in the first two to three years of life. But when that appears, the window has already closed. Tomás looks well because we are acting now — before he starts to look ill. That is exactly what we need: to act when there is still something surgery can do.)
Esperanza opened her eyes. She looked at Tomás, who was asleep in Miguel’s arms, his chest rising and falling evenly. “Lo que estamos haciendo esta semana no es operar a un bebé que se ve bien,” she said slowly, as if working through it. “Estamos operando antes de que se vea mal.” (What we are doing this week is not operating on a baby who looks fine. We are operating before he starts to look ill.)
“Exactamente eso,” Carmen said. (Exactly that.)
Esperanza was quiet for a long moment. Then she straightened in her chair. “¿Qué necesita que hagamos nosotros esta noche para prepararlo?” (What do you need us to do tonight to prepare him?)
Carmen had been waiting for that question. It was the question that meant the family was ready. “Nada de comer o tomar después de la medianoche. Llegar a las cinco y media de la mañana. Traer el chupete de Tomás y la cobijita que le gusta. El equipo de cirugía los verá a las cinco cuarenta y cinco.” (Nothing to eat or drink after midnight. Arrive at five-thirty in the morning. Bring Tomás’s pacifier and the blanket he likes. The surgical team will see you at five forty-five.)
Scenario 3: Valentina Morales-Torres — 4 months old, Dallas, Texas
Valentina Morales-Torres had been born at 27 weeks and 2 days at Parkland Memorial Hospital in Dallas. She had weighed 950 grams at birth. Her parents Claudia, 27, a medical office secretary, and Ramón, 30, a warehouse supervisor, had been in the NICU for the first three weeks of her life when the phone call came at 2 AM: Valentina had developed necrotizing enterocolitis. The neonatologist had explained that NEC was an intestinal emergency in premature infants in which the bowel wall became ischemic and infected. The on-call pediatric surgeon had met them in the waiting room at 4 AM with a consent form. Valentina had been taken to the operating room at 6 AM.
The surgery had saved her life. It had also required removing 55 percent of her small bowel: the segment from the mid-jejunum through the terminal ileum, including the ileocecal valve. Thirty-five centimeters of small bowel remained. An end-ileostomy had been created to allow the remaining bowel to recover before eventual reconnection.
Three months had passed. Valentina was now 4 months old, corrected age 1 month. She had been moved from the NICU to the pediatric surgical unit six weeks ago. She was tolerating 15 mL per hour of maternal breast milk through a nasogastric tube — a number that had taken six weeks of careful advancement to reach. She was receiving 60 percent of her nutritional needs from the TPN running through her central line and the rest from the enteral feeds. She was growing — slowly, but growing.
The discharge planning team had met with Claudia and Ramón the previous week. Valentina would be discharged to home with home parenteral nutrition — TPN through the central line, administered for 16 hours each day by Claudia and Ramón with nursing supervision, plus continued tube feeding advancement at home with the intestinal rehabilitation team outpatient. The expected duration before TPN could potentially be weaned: 6 to 9 months, with the caveat that some children with short bowel syndrome required longer.
Claudia had heard “6 to 9 months” and something in her face had changed. She had been awake in this hospital for three months. She had learned to hang TPN bags, change central line dressings, manage the NG tube. She had been willing to do all of it because she had thought “eventually” was coming soon. Six to 9 months was not soon.
“Enfermera — Valentina está tolerando la leche materna. Está absorbiendo. Yo sé que no es perfecto, pero está mejor. ¿Por qué no podemos ir quitando la nutrición por la vena si ella está comiendo por el estómago?” (Nurse — Valentina is tolerating breast milk. She is absorbing. I know it is not perfect, but she is better. Why can’t we start removing the IV nutrition if she is eating through her stomach?)
Ramón added, “Y la línea central — le entra infección con esa línea. Ya tuvo una.” (And the central line — she gets infections through that line. She already had one.)
Both points were accurate. Valentina was tolerating enteral feeds. She had had one central-line associated bloodstream infection six weeks ago, treated successfully with antibiotics and a line change. Claudia and Ramón understood exactly what was at stake. They were not asking out of impatience; they were asking because they had watched their daughter fight for three months and they wanted to understand why the battle was not closer to over.
Pediatric gastroenterology and intestinal rehabilitation nurse Mariana Castro-Velarde had been the primary coordinator for Valentina’s care since the surgery. She had learned, with short bowel syndrome families, that the most effective approach was to explain TPN not as the problem to be removed but as one half of a two-part strategy — and to give the family a mental model for how the strategy led to the outcome they were already working toward.
“Claudia, Ramón — quiero explicarles algo que se llama adaptación intestinal, porque es lo que hace que la situación de Valentina sea diferente de la de un bebé que simplemente tiene el intestino irritado y necesita tiempo. La adaptación intestinal es el proceso por el cual el intestino que quedó — esos 35 centímetros — puede llegar a absorber lo suficiente para que Valentina no necesite la nutrición por vena. No es que el intestino va a crecer más. Es que cada centímetro de intestino que tiene puede mejorar su propia capacidad de absorción — las vellosidades se alargan, las criptas se hacen más profundas, la superficie absorbente por centímetro aumenta dos o cuatro veces. Al final de ese proceso, el mismo intestino que hoy absorbe un 40 por ciento de lo que Valentina necesita podría absorber el 80 o el 100 por ciento.” (Claudia, Ramón — I want to explain something called intestinal adaptation, because it is what makes Valentina’s situation different from a baby who simply has an irritated intestine and needs time. Intestinal adaptation is the process by which the intestine that remains — those 35 centimeters — can eventually absorb enough so that Valentina does not need IV nutrition. It is not that the intestine will grow more. It is that each centimeter of intestine she has can improve its own absorption capacity — the villi lengthen, the crypts deepen, the absorptive surface per centimeter increases two to four times. At the end of that process, the same intestine that today absorbs 40 percent of what Valentina needs could absorb 80 or 100 percent.)
Claudia was listening intently. “¿Cuánto tiempo tarda eso?” (How long does that take?)
“Entre 12 y 24 meses desde la cirugía. Depende de cuánto intestino quedó, de si quedó la válvula ileocecal — que en el caso de Valentina no quedó, lo que hace el proceso un poco más largo — y de qué tan bien avanza la alimentación enteral. Valentina tiene 4 meses de vida corrected, llegó a 15 mL por hora, y la adaptación ya está ocurriendo. Está en el camino.” (Between 12 and 24 months from the surgery. It depends on how much intestine remains, whether the ileocecal valve was preserved — which in Valentina’s case it was not, which makes the process a bit longer — and how well enteral feeding advances. Valentina is 4 months corrected age, has reached 15 mL per hour, and the adaptation is already occurring. She is on the path.)
Ramón leaned forward. “Pero si la alimentación está avanzando, ¿por qué no podemos ir bajando la nutrición por vena al mismo ritmo?” (But if the feeding is advancing, why can’t we lower the IV nutrition at the same rate?)
“Voy a explicarles exactamente por qué, porque es la parte más importante: los 15 mL por hora que Valentina está tolerando representan quizás el 35 o 40 por ciento de sus necesidades calóricas totales para crecer. No el 100. La adaptación intestinal que va a llevarla al 80 o 100 por ciento todavía no ocurrió. Si bajamos la nutrición por vena a ese 35 o 40 por ciento que la alimentación enteral está cubriendo, Valentina no tendrá suficiente energía para crecer, para la adaptación del intestino, y para el desarrollo del cerebro. La desnutrición a los cuatro meses de edad tiene consecuencias neurológicas que tampoco se recuperan.” (I am going to explain exactly why, because it is the most important part: the 15 mL per hour that Valentina is tolerating represents perhaps 35 to 40 percent of her total caloric needs to grow. Not 100. The intestinal adaptation that will take her to 80 or 100 percent has not happened yet. If we lower the IV nutrition to that 35 to 40 percent that enteral feeding is covering, Valentina will not have enough energy to grow, for intestinal adaptation, and for brain development. Malnutrition at four months of age has neurological consequences that cannot be recovered either.)
Claudia was very still. “Entonces la nutrición por vena no se puede bajar hasta que el intestino esté listo para tomar el relevo.” (So the IV nutrition cannot be lowered until the intestine is ready to take over.)
“Exactamente. Y la alimentación enteral — la leche materna que Valentina está recibiendo — no es solo nutrición. Es la señal que estimula la adaptación. La alimentación enteral activa factores de crecimiento en la pared del intestino — GLP-2, EGF, IGF-1 — que son los que producen el alargamiento de las vellosidades y el crecimiento de las criptas. Si pusiéramos a Valentina solo en nutrición por vena sin alimentación enteral, el intestino no tendría la señal para adaptarse. Eso es lo opuesto de lo que queremos. Las dos cosas al mismo tiempo — la leche para enseñar al intestino, la vena para sostener a Valentina mientras aprende — es exactamente el plan.” (Exactly. And enteral feeding — the breast milk Valentina is receiving — is not just nutrition. It is the signal that stimulates adaptation. Enteral feeding activates growth factors in the intestinal wall — GLP-2, EGF, IGF-1 — which are what produce the lengthening of villi and the growth of crypts. If we put Valentina on IV nutrition only without enteral feeding, the intestine would not have the signal to adapt. That is the opposite of what we want. Both things at the same time — the milk to teach the intestine, the IV to support Valentina while it learns — is exactly the plan.)
Ramón sat back. “¿Y las infecciones de la línea?” (And the line infections?)
“El riesgo de infecciones de la línea central es la parte más seria del plan a domicilio, y la capacidad que han demostrado ustedes dos para manejar el catéter — Claudia, usted ha hecho los cambios de apósito de manera impecable durante seis semanas — es lo que hace que el alta domiciliaria sea posible. En casa el riesgo de infección es menor que en el hospital, porque los hospitales tienen bacterias resistentes que el domicilio no tiene. Las reglas son: lavado de manos estricto antes de cada manipulación, inspección del sitio de inserción cada día, y si aparece fiebre — temperatura por encima de 38 grados rectales — llamar a la línea de urgencias y ir al servicio de urgencias con ella sin esperar.” (The risk of central line infections is the most serious part of the home plan, and the capacity both of you have shown to manage the catheter — Claudia, you have done the dressing changes impeccably for six weeks — is what makes home discharge possible. At home the infection risk is lower than in the hospital, because hospitals have resistant bacteria that the home does not have. The rules are: strict hand washing before every manipulation, inspection of the insertion site every day, and if fever appears — temperature above 38 degrees rectally — call the emergency line and go to the emergency room without waiting.)
Claudia had been listening with the focused attention of someone taking an exam. “¿Y la meta — 6 a 9 meses para quitarle la línea — cómo sabremos que estamos llegando?” (And the goal — 6 to 9 months to remove the line — how will we know we are getting there?)
“Hay tres señales que muestran adaptación: primero, el estómago tolera volúmenes crecientes de leche sin diarrea osmótica. Segundo, el peso de Valentina sube a buen ritmo incluso cuando bajamos el porcentaje de la nutrición por vena en los ciclos de ajuste. Tercero, en los análisis de sangre, la citrulina — que es un aminoácido producido solo por los enterocitos del intestino delgado — va subiendo, lo que indica que hay más masa mucosa funcionando. Cuando esas tres señales estén alineadas y el intestino esté cubriendo el 70 u 80 por ciento de las necesidades, empezamos a retirar la nutrición por vena en etapas. Es un proceso gradual, pero cada semana que avanzamos la alimentación enteral es una semana de adaptación. El intestino de Valentina ya está aprendiendo — simplemente necesita tiempo.” (There are three signs that show adaptation: first, the stomach tolerates increasing volumes of milk without osmotic diarrhea. Second, Valentina’s weight rises at a good rate even when we lower the percentage of IV nutrition in adjustment cycles. Third, on blood tests, citrulline — an amino acid produced only by the enterocytes of the small intestine — is rising, indicating that there is more functional mucosal mass. When those three signs are aligned and the intestine is covering 70 to 80 percent of needs, we begin withdrawing IV nutrition in stages. It is a gradual process, but every week that enteral feeding advances is a week of adaptation. Valentina’s intestine is already learning — it simply needs time.)
Ramón was quiet for a moment. He looked at Claudia. She had been reaching for Valentina’s hand through the isolette port.
“La lactancia materna que usted quiere darle a Valentina es exactamente el destino,” Mariana said. “El camino requiere más tiempo del que quisiéramos. Pero el camino está funcionando.” (The breastfeeding you want to give Valentina is exactly the destination. The path requires more time than we would like. But the path is working.)
Claudia did not say anything. She was watching her daughter’s fingers curl around the tube of the feeding line — the small, deliberate grip of a baby who had been fighting since she was 950 grams and had not stopped. “Déjeme practicar el cambio de apósito una vez más antes del alta. Quiero asegurarme.” (Let me practice the dressing change one more time before discharge. I want to make sure.)